SERENTIS
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.
SERENTIS
Industry:
Biopharma Health Care Medical Pharmaceutical
Founded:
2006-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.serentis-pharma.com
Total Employee:
11+
Status:
Active
Total Funding:
30.54 M USD
Technology used in webpage:
Nginx Baidu Analytics Peg Technic
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2007-10-02 | Surface Therapeutics Ltd. | Surface Therapeutics Ltd. acquired by Serentis | N/A |
Investors List
Apposite Capital
Apposite Capital investment in Series A - Serentis
East Hill Advisors
East Hill Advisors investment in Series A - Serentis
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Serentis
Novo Holdings
Novo Holdings investment in Series A - Serentis
Novo Holdings
Novo Holdings investment in Series A - Serentis
Apposite Capital
Apposite Capital investment in Series A - Serentis
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Serentis
Official Site Inspections
http://www.serentis-pharma.com
Unable to get host informations!!!
